Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Up 5.56%
As of Monday, August 17, Cardiol Therapeutics Inc.’s CRDL share price has surged by 5.56%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Commentary & Analysis
Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Up 8.88%
As of Thursday, August 13, Cardiol Therapeutics Inc.’s CRDL share price has surged by 8.88%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Up 5.65%
As of Thursday, July 30, Cardiol Therapeutics Inc.’s CRDL share price has surged by 5.65%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Down 5.28%
As of Friday, July 24, Cardiol Therapeutics Inc.’s CRDL share price has dipped by 5.28%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Up 7.21%
As of Thursday, July 16, Cardiol Therapeutics Inc.’s CRDL share price has surged by 7.21%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $221.0 | $618.0 | 28% |
|
| Shares Out (Mil) | 80.9 | 44.8 | 58% |
|
| Institutional Ownership | 79.0% | 85.3% | 48% |
|
| Float (Mil) | 96.3 | 47.4 | 60% |
|
| Beta | 0.47 | 0.70 | 27% |
|
| Avg Daily Volume (000s) | 1,445 | 390 | 77% |
|
| Price Change (52-week) |
65.8% | 68.6% | 84% |
|
| Growth | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (8.8%) | (1.6%) | 30% |
|
| EPS (5yr) | 12.2% | 14.9% | 51 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (19.7%) | (14.9%) | 34% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 3 | |
| Current EPS | ($0.058) | ($0.236) | ($0.220) | |
| Month Ago EPS | ($0.075) | ($0.261) | ($0.203) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.075) | ($0.261) | ($0.203) | |
| Year/Year Chg | 56.8% | (16.9%) | (134.9%) | |
| Financials | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $291 | na |
|
| Net Income (TTM) (Mil) | ($24) | ($11) | 22% |
|
| EPS (TTM) | ($0.236) | ($0.700) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($17) | ($6) | 16% |
|
| Net Cash Flow (TTM) (Mil) | $6 | $5 | 53% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $204 | $450 | 26% |
|
| Valuation | CRDL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 12.60 | 2.78 | 92% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.0% | na |
|
| Net Margin | na | (2.3%) | na |
|
| ROA | (136.0%) | (22.4%) | 4% |
|
| ROE | (187.6%) | (20.2%) | 4% |
|
| Liabilities to Assets | 18.2% | 32.2% | 12% |
|
| F-Score | 4 | 3 | 34% |
|
Cardiol Therapeutics Inc. did not pass any screens on 8/20/2026.
